The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II diabetic subjects

Diabetologia

Volumn 43, Issue 9, 2000, Pages 1099-1106

  Yudkin, J S ^a   Panahloo, A ^a   Stehouwer, C ^b   Emeis, J J ^c   Bulmer, K ^a   Mohamed Ali, V ^a   Denver, A E ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c TNO   (Netherlands)

Author keywords

C reactive protein; Endothelial dysfunction; Glycaemic control; Insulin; Insulin resistance; Interleukin 6; Sulphonylureas; Tumour necrosis factor

Indexed keywords

ACUTE PHASE PROTEIN; ALBUMIN; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRONECTIN; GLIBENCLAMIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HUMAN INSULIN; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; NEUTRAL INSULIN; SULFONYLUREA DERIVATIVE; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR;

ACUTE PHASE RESPONSE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC DIET; FEMALE; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN SENSITIVITY; MALE; METABOLIC CLEARANCE RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM;

ACUTE-PHASE PROTEINS; ALBUMINURIA; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FEMALE; FIBRINOGEN; FIBRONECTINS; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INTERLEUKIN-6; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS; THROMBOMODULIN; TUMOR NECROSIS FACTOR-ALPHA; VON WILLEBRAND FACTOR;

EID: 0033821518     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051500     Document Type: Article

References (63)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type II diabetes (UKPDS 33)
3. Endothelial dysfunction and pathogenesis of diabetic angiopathy
4. How heterogeneous is microalbuminuria in diabetes mellitus? The case for 'benign' and 'malignant' microalbuminuria
5. Insulin sensitivity and vascular disease in insulin-dependent diabetics
6. Role of insulin resistance in human disease
7. Endothelial dysfunction: Cause of the insulin resistance syndrome
8. C-reactive protein in healthy subjects - Associations with obesity, insulin resistance and endothelial dysfunction. A potential role for cytokines originating from adipose tissue?
9. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance
10. Human subcutaneous adipose tissue releases IL6 but not TNF-α in vivo
11. Human endothelial cells produce IL-6. Lack of responses to exogenous IL-6
12. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF- and obesity-in-duced insulin resistance
13. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment
14. Interleukin-6 and the acute phase response
15. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men
16. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984-1992
17. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study
18. C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon?
19. C-reactive protein induces human peripheral blood monocytes to synthesise tissue factor
20. Is Type II diabetes mellitus a disease of the innate immune system?
21. Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus
22. Glycation and diabetic complications
23. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions
24. Hyper-glycemic pseudohypoxia and diabetic complications
25. Amelioration of vascular dysfunction in diabetic rats by an oral PKC inhibitor
26. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins
27. Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetes
28. A comparison of 3 methods for assessing insulin sensitivity in subjects with normal and abnormal glucose tolerance
29. Associations of proinsulin-like molecules with lipids and fibrinogen in non-diabetic subjects - Evidence against a modulating role for insulin
30. Elevated plasma levels of ED1 + ('cellular') fibronectin in patients with vascular injury
31. Design and validation of a new immunoassay for soluble forms of thrombomodulin and studies on plasma
32. A sensitive ELISA for von Willebrand factor (vWF:Ag)
33. Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy
34. Rapid competitive enzymoimmunoassay for albumin in urine
35. Von Willebrand factor is an acute phase reactant in man
36. Endothelial cell activation. A central pathophysiological process
37. Inflammation, the acute phase response and atherosclerosis
38. Elevated glucose concentrations increase factor VIIIR: AG levels in human umbilical vein endothelial cells
39. Modulation by high glucose of adhesion molecule expression in cultured endothelial cells
40. Elevated levels of soluble E-selectin in patients with IDDM and NIDDM: Relation to metabolic control
41. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial ceils and in mice. A potential mechanism for the accelerated vasculopathy of diabetes
42. Distinct associations of HbA(1C) and the urinary excretion of pentosidine, an advanced glycosylation end product, with markers of endothelial function in insulin-dependent diabetes mellitus
43. Amadori albumin in type I diabetic patients: Correlation with markers of endothelial function, association with diabetic nephropathy, and localisation in retinal capillaries
44. Acute hyperglycemia attenuates endothelium-dependent vasodilatation in humans in vivo
45. Microvascular function in Type II (non-insulin-dependent) diabetes: Improved vasodilatation after one year of good glycaemic control
46. Insulin therapy improves endothelial function in Type II diabetes
47. Elevated concentrations of soluble E-selectin and vascular cell adhesion molecule-1 in NIDDM. Effect of intensive insulin treatment
48. Von Willebrand Factor and development of diabetic nephropathy in IDDM
49. Haemostatic abnormalities persist despite glycaemic improvement by insulin therapy in lean Type II diabetic patients
50. The effect of diabetes regulation on platelet release, fibrinolysis and coagulation tests, before and after stimulation with DDAVP
51. Relationship between insulin resistance, soluble adhesion molecules, and mononuclear cell binding in healthy volunteers
52. Relationships of urinary albumin and Nacetylglucosaminidase to glycaemia and hypertension at diagnosis of Type II (non-insulin-dependent) diabetes mellitus and after 3 months diet therapy (UKPDS IX)
53. Kidney function in newly diagnosed Type II (non-insulin-dependent) diabetic patients, before and during treatment
54. Sustained reduction of proteinuria in Type II (non-insulin-dependent) diabetes following diet-induced reduction of hyperglycaemia
55. Normalisation of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatment
56. Glucose-dependent interleukin-6 and tumor necrosis factor production by human peripheral blood monocytes in vitro
57. Role of oxidative stress in development of complications in diabetes
58. Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase plasma protein genes
59. Reduced fibrinogen survival in diabetes mellitus. A reversible phenomenon
60. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease
61. Plasma fibrinogen in NIDDM: The Rotterdam Study
62. Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins. Veterans Affairs Cooperative Study in Type II Diabetes Mellitus